Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27680962 | 0.84 | SLC6A2 (0.35) | CYP17A1CYP1A2ADRA1A | |
| SCHEMBL22678981 | 0.81 | CNR2 (0.43) | CNR2 | |
| SCHEMBL13750403 | 0.78 | MAPK1 (0.33) | CNR2 | |
| SCHEMBL21539535 | 0.78 | ADRA1A (0.34) | CYP17A1CYP1A2ADRA1A | |
| SCHEMBL2600522 | 0.78 | CCNK (0.35) | — | |
| SCHEMBL12293132 | 0.76 | CNR1 (0.38) | CYP1A2CNR2ADRA1A | |
| SCHEMBL15072856 | 0.76 | MAPK1 (0.46) | CYP17A1CYP1A2ADRA1A | |
| SCHEMBL24650682 | 0.76 | — | — | |
| SCHEMBL25071164 | 0.75 | — | — | |
| SCHEMBL12866736 | 0.74 | CYP17A1 (0.36) | CYP17A1CYP1A2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-12024500-B2 | Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | DICE MOLECULES SV, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20220160686-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-10973805-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20210032222-A1 | FIVE-MEMBERED RING-SUBSTITUTED PYRIDAZINOL COMPOUNDS AND DERIVATIVES, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND APPLICATIONS THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2021-02-04 | — | — | US | disclosed |
| US-20200360353-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | DICE MOLECULES SV, INC. | 2020-08-06 | — | — | US | disclosed |
| US-10023576-B2 | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023576-B2 | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170355698-A1 | HETEROARYL SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355698-A1 | HETEROARYL SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | PFIZER INC. (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024500-B2 | Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof | DDT, CYP3A5, CYP4B1 | CYP17A1 641/4885CYP1A2 15/4885CNR2 1446/4885 |
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | IL17A, IL2, IL15 | CYP17A1 244/4885CYP1A2 1937/4885CNR2 2376/4885 |
| US-10973805-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | EED, EZH2, BMI1 | CYP17A1 2693/4885CYP1A2 1485/4885CNR2 3385/4885 |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | BCLAF1, EED, BCL3 | CYP17A1 1778/4885CYP1A2 3516/4885CNR2 4271/4885 |
| US-10023576-B2 | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | PIK3R3, PIK3R5, PIK3R1 | CYP17A1 2009/4885CYP1A2 1964/4885CNR2 733/4885 |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | IL17A, IL2, IL15 | CYP17A1 244/4885CYP1A2 1937/4885CNR2 2376/4885 |
| US-20220160686-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | CYP17A1 2693/4885CYP1A2 1485/4885CNR2 3385/4885 |
| US-20170355698-A1 | HETEROARYL SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS | PIK3R3, PIK3R5, PIK3R1 | CYP17A1 2009/4885CYP1A2 1964/4885CNR2 733/4885 |
| US-20200360353-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | CYP17A1 2728/4885CYP1A2 1600/4885CNR2 3498/4885 |
| US-20210032222-A1 | FIVE-MEMBERED RING-SUBSTITUTED PYRIDAZINOL COMPOUNDS AND DERIVATIVES, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND APPLICATIONS THEREOF | CBR3, CBR1, CYP8B1 | CYP17A1 709/4885CYP1A2 21/4885CNR2 265/4885 |
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | BACE1, BACE2, APH1B | CYP17A1 1137/4885CYP1A2 1979/4885CNR2 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.